Can you believe it, Paul? Oxford Club Chief Income Strategist Marc Lichtenfeld says THIS small company is poised to see gains that could rival some of the biggest in the history of the biotech sector... Like Gilead. In January 1995, it closed at just $0.29 a share. In June 2015, it hit $122. That's a gain of more than 42,000% in 20 years. 
Or what about Biogen... In early 1995, it traded for $0.37 a share. In March 2015, it hit almost $476. That was enough to hand lucky investors gains of up to 128,543%. 
Then there's Amgen. Back in 1985, investors could've picked up shares at $0.10 a pop... And in July 2020, they could've cashed them in for $260 each. That's a jaw-dropping 260,850% gain. 
Gains like these are possible in this sector. (See why HERE.) And yet, they may be only scratching the surface of what's to come... Because Marc's #1 biotech of 2021 could change everything doctors know about medicine forever. Be relentless, Nate P.S. I'm not saying that Marc's #1 biotech is destined to follow the exact path as those rare, extraordinary examples. But even a small fraction of those gains could transform your wealth. Please don't miss this opportunity. Go HERE now. | 
No comments:
Post a Comment